{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017293","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.886685+00:00","generated_at":"2026-06-01T21:43:14.254270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027","bullets":["Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.","R&D expenses $7.8M vs $3.6M YoY; increase driven by product candidate development.","Completed IPO in April 2024; net proceeds $108.0M, extending cash runway to end of 2027.","Initiated Phase 2 trial of PIPE-307 in RRMS; J&J partner plans Phase 2 in depression in 2024.","Nominated third development candidate CTX-343 (LPA1R antagonist); IND submission expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017293","json":"https://secwatch.observer/filing/0001437749-24-017293.json","markdown":"https://secwatch.observer/filing/0001437749-24-017293.md","text":"https://secwatch.observer/filing/0001437749-24-017293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/0001437749-24-017293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/cont20240417_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:43:14.254270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4a81ccdde88139e9359bf9d9764f0504727da13","claim":"Contineum Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/0001437749-24-017293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}